F S&P 500
5,437.25 -0.25 (-0.00%) F Dow Jones
38,561.00 -44.00 (-0.11%) F Nasdaq
19,723.00 +37.50 (+0.19%) E-mini Russell 2000 Index Futur
2,025.80 -3.20 (-0.16%) Petróleo
78.64 +0.19 (+0.24%) Oro
2,335.70 -13.40 (-0.57%)
NervGen Pharma Corp. (NGENF)
NervGen Pharma Corp.
112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4
Canada
778-731-1711
https://www.nervgen.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Michael Kelly | CEO, President & Director | 538.19k | N/D | 1966 |
| Dr. Harold Martin Punnett D.M.D. | Co-Founder & Independent Director | N/D | N/D | N/D |
| Mr. William J. Adams C.A., CPA, CA, CPA | CFO & Corporate Secretary | 313.78k | N/D | 1962 |
| Dr. Daniel D. Mikol M.D., Ph.D. | Chief Medical Officer | 577.19k | N/D | N/D |
| Mr. Brian McAlister | Co-Founder & Advisor | N/D | N/D | N/D |
Descripción
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.
Gestión corporativa
La calificación ISS Governance QuickScore de NervGen Pharma Corp. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
